Current Hematologic Malignancy Reports

, Volume 7, Issue 2, pp 144–152

The Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Therapy of Patients with Acute Lymphoblastic Leukemia

Acute Lymphocytic Leukemia (F Ravandi, Section Editor)

DOI: 10.1007/s11899-012-0116-3

Cite this article as:
Kebriaei, P. & Poon, L.M. Curr Hematol Malig Rep (2012) 7: 144. doi:10.1007/s11899-012-0116-3


Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an effective post-remission therapy in patients with acute lymphoblastic leukemia (ALL), but is associated with significant toxicity, so the optimal timing and use of this modality remains an issue of debate. Increased advances in reduced-intensity transplant preparative regimens and alternative donors has increased the accessibility of allogeneic transplantation. A risk adapted paradigm, using minimal residual disease analysis, may help in the selection of patients at highest risk for relapse, who may benefit most from alloHSCT. In this review, we summarize the indications for allogeneic transplantation within the risk-oriented paradigm, and also explore the latest literature on reduced intensity transplant regimens, as well as alternative donor transplantation for patients with ALL.


Acute lymphoblastic leukemiaAllogeneic hematopoietic stem cell transplantationMinimal residual diseaseHaplo-identical stem cell transplantationCord blood transplantationReduced intensity transplant regimenPhiladelphia chromosome positive ALL

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Stem Cell Transplantation and Cellular TherapyMD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Stem Cell TransplantThe University of Texas, MD Anderson Cancer CenterHoustonUSA